- Home
- UAN vs DMRA Comparison
UAN vs DMRA Comparison
Compare UAN & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAN | DMRA |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UAN | DMRA |
|---|---|---|
| Price | $121.56 | $25.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $43.00 |
| AVG Volume (30 Days) | 49.7K | ★ 304.1K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | ★ 61.98 | N/A |
| EPS | ★ 4.72 | N/A |
| Revenue | ★ $606,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.32 | ★ N/A |
| Revenue Growth | ★ 15.36 | N/A |
| 52 Week Low | $81.18 | $16.50 |
| 52 Week High | $139.50 | $28.76 |
Technical Indicators
Market Signals| Indicator | UAN | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 50.46 |
| Support Level | $120.05 | $24.80 |
| Resistance Level | $139.42 | $26.73 |
| Average True Range (ATR) | 4.66 | 1.56 |
| MACD | -0.98 | 0.12 |
| Stochastic Oscillator | 10.32 | 66.89 |
Price Performance
Historical ComparisonAbout UAN CVR Partners LP
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About DMRA Damora Therapeutics Inc. Common Stock
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.